Our # 1 Biotech Stock for October

Dear Investor,

On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of genetic software that can "Cut & Paste" any disease from your body.

This revolutionary new kind of treatment will not just change medicine -

It has the potential to eliminate genetic disease from our species.

If that sounds like science fiction, consider this -

• The Nobel Prize Committee is calling it "The Holy Grail of Medicine"
• The Wall Street Journal reports the company is "transforming medicine."
• 60 Minutes reports the company is "revolutionizing the search for new drugs."

And the biggest drug companies have rushed to invest over a $1 billion in the past year alone -

Juno Pharma invested $700 million.

Glaxo SmithKline invested $350 million.

Johnson and Johnson invested $292 million.

That's on top of the $120 million Bill Gates and Google Ventures already invested into this.

The list goes on and on...

Never before has so much money invested in a new treatment so quickly.

And because of that, it's going to create more millionaires than any other single breakthrough in history. More than the internet, more than computers, more than cars.

Investor's Business Daily estimates the market is worth at least $75 billion market.

But right now, its stock price is just a tiny fraction of that size.

Our research proves that anyone who gets in today could make 46,751%!

That's if the company doesn't get taken over for fast 300% gains first.

CLICK HERE to see how you can profit from this rare opportunity>>>

Sincerely,

Dylan Jovine
Behind the Markets
"The Buck Stops Here"

Stockguru LLC 711 SW 24th Ave Boynton, Beach, FL 33435 This email is being sent from Investing Chatter. If you no longer wish to receive Investing Chatter emails, please click to unsubscribe.

DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.